Why a universal antiretroviral regimen?
作者信息
Flexner Charles W, Clayden Polly, Venter Willem D F
机构信息
aDivisions of Clinical Pharmacology and Infectious Diseases, School of Medicine and Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA bHIV-Base, London, UK cWits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa.
出版信息
Curr Opin HIV AIDS. 2017 Jul;12(4):315-317. doi: 10.1097/COH.0000000000000390.
Abstract
摘要
相似文献
1
Why a universal antiretroviral regimen?为什么采用通用抗逆转录病毒疗法？
Curr Opin HIV AIDS. 2017 Jul;12(4):315-317. doi: 10.1097/COH.0000000000000390.
2
HIV/AIDS.人类免疫缺陷病毒/获得性免疫综合征
Infect Dis Clin North Am. 2014 Sep;28(3):xv-xvi. doi: 10.1016/j.idc.2014.07.001.
3
Novel antiretroviral agents and universal access to HIV care.新型抗逆转录病毒药物与普及艾滋病毒治疗服务
Lancet HIV. 2016 Jan;3(1):e2-3. doi: 10.1016/S2352-3018(15)00244-1. Epub 2015 Dec 12.
4
The AIDS epidemic--a progress report from Mexico City.艾滋病疫情——来自墨西哥城的进展报告。
N Engl J Med. 2008 Aug 28;359(9):885-7. doi: 10.1056/NEJMp0805761.
5
6
First-line antiretroviral therapy for HIV-infected children.针对感染艾滋病毒儿童的一线抗逆转录病毒疗法。
AIDS. 2015 Jun 19;29(10):1261-2. doi: 10.1097/QAD.0000000000000727.
7
Comment on: antiretroviral treatment French guidelines 2013: economics influencing science.评论：《2013年法国抗逆转录病毒治疗指南：影响科学的经济学》
J Antimicrob Chemother. 2014 Oct;69(10):2881-2. doi: 10.1093/jac/dku186. Epub 2014 May 30.
8
Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir.
HIV Clin Trials. 2008 Mar-Apr;9(2):140-1. doi: 10.1310/hct0902-140.
9
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.英国HIV协会2008年抗逆转录病毒疗法治疗HIV-1感染成人指南。
HIV Med. 2008 Oct;9(8):563-608. doi: 10.1111/j.1468-1293.2008.00636.x.
10
Highlights on HIV eradication in 2013.2013年艾滋病消除工作要点。
AIDS. 2014 Jan 2;28(1):1-7. doi: 10.1097/01.aids.0000433241.78739.79.
引用本文的文献
1
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial.南非采用适应性评估方法对移动医疗和常规依从性支持干预措施进行评估，以优化耐多药结核病和艾滋病毒新治疗方案的效果（ADAP-TIV）：一项适应性随机对照试验研究方案。
Trials. 2023 Dec 1;24(1):776. doi: 10.1186/s13063-023-07520-9.
2
Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?将孕妇纳入抗逆转录病毒药物研究：需要做些什么才能向前推进？
J Int AIDS Soc. 2019 Sep;22(9):e25372. doi: 10.1002/jia2.25372.
3
Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration.推动儿科艾滋病治疗议程：以科学、创新和合作。
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 1(1):S32-S39. doi: 10.1097/QAI.0000000000001747.
4
Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.迈向通用抗逆转录病毒疗法：妊娠和母乳喂养的特殊考量
Curr Opin HIV AIDS. 2017 Jul;12(4):359-368. doi: 10.1097/COH.0000000000000386.
本文引用的文献
1
Drug interactions and the role of pharmacokinetic trials in guiding choices in first-line HIV therapy in low-income and middle-income countries.药物相互作用以及药代动力学试验在低收入和中等收入国家一线抗逆转录病毒疗法治疗选择指导中的作用。
Curr Opin HIV AIDS. 2017 Jul;12(4):377-382. doi: 10.1097/COH.0000000000000384.
2
Antiretroviral dose optimization: the future of efavirenz 400 mg dosing.抗逆转录病毒药物剂量优化：依非韦伦400毫克给药的未来。
Curr Opin HIV AIDS. 2017 Jul;12(4):339-342. doi: 10.1097/COH.0000000000000385.
3
Dealing with large-scale supply lines when introducing new regimens.在引入新治疗方案时应对大规模供应链问题。
Curr Opin HIV AIDS. 2017 Jul;12(4):408-413. doi: 10.1097/COH.0000000000000387.
4
The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen.ADVANCE研究：一项评估候选通用抗逆转录病毒疗法方案的开创性试验。
Curr Opin HIV AIDS. 2017 Jul;12(4):351-354. doi: 10.1097/COH.0000000000000389.
5
Accelerating access and scale-up of optimized ART in low-income and middle-income countries: a call for a coordinated end-to-end approach.加快低收入和中等收入国家优化抗逆转录病毒治疗的可及性并扩大其规模：呼吁采取协调一致的端到端方法。
Curr Opin HIV AIDS. 2017 Jul;12(4):383-389. doi: 10.1097/COH.0000000000000383.
6
The role of activists in access to HIV and tuberculosis treatment and prevention.
Curr Opin HIV AIDS. 2017 Jul;12(4):398-402. doi: 10.1097/COH.0000000000000381.
7
Can the generic antiretroviral industry support access to a universal antiretroviral regimen?通用抗逆转录病毒药物行业能否支持普及抗逆转录病毒治疗方案的可及性？
Curr Opin HIV AIDS. 2017 Jul;12(4):390-397. doi: 10.1097/COH.0000000000000382.
8
Toward a universal antiretroviral regimen: special considerations of pregnancy and breast feeding.迈向通用抗逆转录病毒疗法：妊娠和母乳喂养的特殊考量
Curr Opin HIV AIDS. 2017 Jul;12(4):359-368. doi: 10.1097/COH.0000000000000386.
9
When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.新型抗逆转录病毒药物何时可被推荐用于低收入和中等收入国家的国家治疗项目：世卫组织智囊团的结果
Curr Opin HIV AIDS. 2017 Jul;12(4):414-422. doi: 10.1097/COH.0000000000000380.
10
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.在资源有限的环境中，下一代一线抗逆转录病毒药物与基于利福平的抗结核治疗的兼容性。
Curr Opin HIV AIDS. 2017 Jul;12(4):355-358. doi: 10.1097/COH.0000000000000376.
Zotero 插件